In the relentless battle against cancer, the immune system’s cytotoxic T cells stand as frontline warriors, tasked with identifying and eradicating malignant cells. Nonetheless, their capacity to execute these functions is often compromised within the hostile milieu of solid tumors. This adversity in the tumor microenvironment (TME) culminates in a profound dysfunction termed “terminal exhaustion,” a state in which T cells become metabolically impaired and genetically reprogrammed, leading to diminished cellular proliferation and extinguished cytolytic activity. The conundrum posed by these exhausted T cells has long challenged cancer immunotherapy, significantly contributing to resistance against treatments designed to rekindle immune-mediated tumor clearance.
Central to terminal exhaustion is the accumulation of defective mitochondria within T cells—organelles that conventionally act as bioenergetic hubs fueling cellular activity. Loss of mitochondrial integrity and function not only deprives T cells of necessary energy reserves but also orchestrates shifts in gene expression that anchor these cells in a dysfunctional, non-proliferative state. Despite recognition of this connection, the mechanistic link between mitochondrial damage and transcriptional reprogramming remained obscure until recently. A groundbreaking study spearheaded by Yingxi Xu and Ping-Chih Ho at Ludwig Lausanne unveils the intricate molecular cascade connecting mitochondrial demise to T cell exhaustion, spotlighting the pivotal role of heme signaling.
This newly elucidated pathway identifies heme—a porphyrin ring-containing iron molecule historically noted for its role in oxygen transport—as a hitherto unrecognized agent facilitating T cell dysfunction. Typically embedded within mitochondrial proteins, heme becomes aberrantly released amidst mitochondrial degradation failures endemic to exhausted T cells in the TME. Xu and colleagues demonstrate that the proteasome, the cell’s principal protein degradation machinery, becomes hyperactivated under these conditions and preferentially dismantles mitochondrial heme-containing proteins. This selective degradation engenders an intracellular surge of free heme, which is subsequently converted into a distinct regulatory form.
The regulatory heme translocates into the nucleus via the transporter protein PGRMC2, where it exerts profound effects on gene expression by inducing degradation of a key transcription factor. This event triggers a cascade of molecular alterations culminating in the activation of exhaustion-associated genetic programs. Intriguingly, the researchers showed that genetic ablation of PGRMC2 interrupts this deleterious sequence, preserving T cells in a metabolically and functionally resilient state. Such findings highlight PGRMC2 as a promising therapeutic target for reinvigorating anti-tumor immunity.
Innovatively, this work also bridges these mechanistic insights to clinical immunotherapeutic strategies, particularly the chimeric antigen receptor (CAR) T cell therapy paradigm. CAR-T therapy, a transformative approach in cancer treatment whereby patient-derived T cells are engineered ex vivo to target cancer-specific antigens, often succumbs to similar exhaustion pathways post-infusion, limiting its long-term efficacy. Xu and Ho’s team employed a pharmacological intervention using bortezomib, a proteasome inhibitor conventionally approved for leukemia treatment, during the CAR-T cell manufacturing process. Remarkably, transient, low-dose administration of bortezomib curtailed exhaustion-associated transcriptional programs within CAR-T cells, fostering a durable intracellular milieu conducive to sustained proliferation and cytotoxic performance.
Clinical correlations further substantiated these preclinical observations. Analysis of CAR-T cells from B cell acute lymphoblastic leukemia (B-ALL) patients revealed that heightened proteasome activity within these cells portended poorer therapeutic outcomes, whereas diminished activity correlated strongly with complete remission and favorable prognoses. This underscores the potential for proteasome modulation as a biomarker and interventional target in enhancing CAR-T efficacy.
The study compellingly reframes T cell exhaustion, not merely as an irreversible endpoint of chronic antigenic stimulation, but as a reversible metabolic and signaling imbalance amenable to therapeutic correction. By dissecting the molecular interplay involving mitochondrial heme processing and proteasomal dynamics, this research provides a conceptual foundation for next-generation cellular immunotherapies aimed at reinvigorating T cell function. These approaches could substantially elevate the potency of immuno-oncology regimens, transforming resistant cancers into tractable diseases.
Furthermore, the implications of their findings extend beyond cancer, potentially influencing fields where T cell exhaustion is implicated, including chronic infections and autoimmune disorders. The integration of metabolic signaling pathways with gene regulation elucidates fundamental principles of immune cell biology that could inspire novel interventions across diverse therapeutic landscapes.
This pioneering investigation was underpinned by a vast network of support from numerous prestigious entities, including the Ludwig Institute for Cancer Research and the Swiss National Science Foundation, evidencing the collaborative efforts propelling advances in cancer immunology. The research outcomes published in Nature exemplify the power of molecular insights to unlock new horizons in immunotherapy.
In summary, Xu, Ho, and colleagues reveal that dysfunctional mitochondrial accumulation triggers a proteasome-dependent heme signaling axis, driving T cell exhaustion through transcriptional reprogramming mediated by regulatory heme and PGRMC2. This discovery not only unveils critical mechanistic underpinnings but also delineates actionable targets such as PGRMC2 and proteasome function modulation with existing drugs like bortezomib. These interventions promise to fortify the metabolic and functional fitness of tumor-targeting T cells, offering renewed hope for durable immune-mediated cancer control.
Subject of Research: Molecular mechanisms underlying T cell exhaustion in cancer and strategies to enhance immunotherapy
Article Title: Proteasome-guided haem signalling axis contributes to T cell exhaustion
News Publication Date: 18 March 2026
Web References:
https://www.nature.com/articles/s41586-026-10250-y
Image Credits: Ludwig Cancer Research
Keywords: T cell exhaustion, cancer immunotherapy, tumor microenvironment, mitochondrial dysfunction, heme signaling, proteasome, CAR-T therapy, PGRMC2, proteasome inhibition, bortezomib, metabolic reprogramming, transcriptional regulation
